carbetocin : Oxytocin in which the hydrogen on the phenolic hydroxy group is substituted by methyl, the amino group on the cysteine residue is substituted by hydrogen, and the sulfur of the cysteine residue is replaced by a methylene group. A synthetic carba-analogue of oxytocin, it is used to control bleeding after giving birth. Like oxytocin, it causes contraction of the uterus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 16681432 |
| CHEMBL ID | 3301668 |
| CHEBI ID | 59204 |
| SCHEMBL ID | 39224 |
| MeSH ID | M0074774 |
| Synonym |
|---|
| carbetocinum |
| CHEBI:59204 , |
| carbetocino |
| 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-methoxybenzyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide |
| DB01282 |
| 1-butanoic acid-2-(o-methyl-l-tyrosine)-1-carbaoxytocin |
| 1-butyric acid-2-(3-(p-methoxyphenyl)-l-alanine)oxytocin |
| carbetocin |
| deamino-2-o-methyltyrosine-1-carbaoxytocin |
| 1-carbaoxytocin, 1-butanoic acid-2-(o-methyl-l-tyrosine)- |
| 1-[6-(2-amino-2-oxo-ethyl)-9-(3-amino-3-oxo-propyl)-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-12-sec-butyl-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]-n-[1-[(2-amino-2-oxo-ethyl)carbamoyl]-3-methyl-butyl]pyrrolidine-2-carboxamide; 2,2,2-t |
| A823503 |
| AKOS015994647 |
| carbetocinum [inn-latin] |
| fe 992097 |
| lv-101 |
| 88twf8015y , |
| 1-carboxytocin, 1-butanoic acid-2-(o-methyl-l-tyrosine)- |
| carbetocin [usan:inn:ban] |
| 1-buttersaeure-2-(3-(4-methoxyphenyl)-l-alanin)oxytocin |
| carbetocino [inn-spanish] |
| who 5014 |
| einecs 253-312-6 |
| unii-88twf8015y |
| fe-992097 |
| CHEMBL3301668 |
| HY-17573 |
| SCHEMBL39224 |
| HS-2007 |
| c45h69n11o12s |
| carbetocin [inn] |
| carbetocin [usan] |
| carbetocin [mart.] |
| carbetocin [who-dd] |
| carbetocin [mi] |
| o-methyl-n-(4-sulfanylbutanoyl)-l-tyrosyl-l-isoleucyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-leucyl-glycinamide cyclic (1->5)-thioether |
| pabal |
| glycinamide, n-(4-mercapto-1-oxobutyl)-o-methyl-l-tyrosyl-l-isoleucyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-leucyl-, cyclic (1->5)-thioether |
| (2s)-2-{[(2s)-1-{[(3r,6s,9s,12s,15s)-12-[(2s)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}pyrrolidin-2-yl]formamido}-n-(carbamoylmethyl)-4-me |
| bdbm50044677 |
| gtpl11169 |
| mfcd01076600 |
| NCGC00485451-02 |
| DTXSID90897527 |
| Q5037853 |
| ethyl?2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxylate |
| carbetocin 100 microg/ml in acetonitrile:methanol |
Cebotocin showed an elevated reporting for adverse hypertension, hypotension, and tachycardia in pharmacovigilance data. No deaths were reported with carbetocin for any of the haemodynamic adverse events.
Administration of carbetocin was well tolerated by all horses and its half-life was 17.
| Excerpt | Reference | Relevance |
|---|---|---|
| "To determine the pharmacokinetic parameters (principally half-life) of carbetocin in horses." | ( Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, following intravenous administration in horses. Davis, J; Pinto, CR; Schramme, AR; Whisnant, CS; Whitacre, MD, 2008) | 0.35 |
| "Administration of carbetocin was well tolerated by all horses and its half-life was 17." | ( Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, following intravenous administration in horses. Davis, J; Pinto, CR; Schramme, AR; Whisnant, CS; Whitacre, MD, 2008) | 0.35 |
| "The half-life of carbetocin is greater than that previously reported for oxytocin (6." | ( Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, following intravenous administration in horses. Davis, J; Pinto, CR; Schramme, AR; Whisnant, CS; Whitacre, MD, 2008) | 0.35 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
The standard carbetocin dosing was 100 µg iv following vaginal and intrapartum Cesarean delivery. The dose-response relationship of carbetOCin in obese women has not yet been determined.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Studies were done with d(COMOT) concerning the dose-response relationship, the influence of the lactation stage on the duration of the milk let-down effect, and the difference between the IV and IM injections." | ( Effect of oxytocin and its long-acting analog on milk let-down and intramammary pressure in healthy lactating sows. Aström, G; Cort, N; Einarsson, S, 1982) | 0.26 |
| " Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM)." | ( Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth. de Groot, AN; Schulz, M; Sporken, JM; van Dongen, PW; van Roosmalen, J; Verbruggen, MM, 1998) | 0.3 |
| "All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18)." | ( Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth. de Groot, AN; Schulz, M; Sporken, JM; van Dongen, PW; van Roosmalen, J; Verbruggen, MM, 1998) | 0.3 |
| " An approach to dosing and choices of agent for the limitation of postpartum haemorrhage is suggested." | ( The use of uterotonic drugs during caesarean section. Dresner, A; Dyer, RA; van Dyk, D, 2010) | 0.36 |
| " The carbetocin was administered as 100 µg intravenous dosage across the trials, while oxytocin was administered intravenously but at varied dosages." | ( Carbetocin for preventing postpartum haemorrhage. Chong, YS; Samuel, M; Su, LL, 2012) | 0.38 |
| " The carbetocin was administered as 100 µg intravenous dosage across the trials, while oxytocin was administered intravenously but at varied dosages." | ( Carbetocin for preventing postpartum haemorrhage. Chong, YS; Samuel, M; Su, LL, 2012) | 0.38 |
| " After equilibration, they were pretreated with oxytocin 10 M (experimental group) or physiologic salt solution (control group) for 2 h and then subjected to dose-response testing with increasing concentrations of oxytocin or carbetocin (10 to 10 M)." | ( In Vitro Comparative Effect of Carbetocin and Oxytocin in Pregnant Human Myometrium with and without Oxytocin Pretreatment. Balki, M; Carvalho, JC; Cole, NM; Erik-Soussi, M; Ramachandran, N, 2016) | 0.43 |
| " Both haemodynamic secondary endpoints will be analysed using a linear regression model, adjusting for the baseline value and the dosage of vasoactive drug given between cord clamping and 1 minute thereafter, in order to investigate superiority of a short-infusion as compared to a bolus application." | ( Efficacy and safety of carbetocin applied as an intravenous bolus compared to as a short-infusion for caesarean section: study protocol for a randomised controlled trial. Bucher, HC; Dell-Kuster, S; Girard, T; Hoesli, I; Lapaire, O; Seeberger, E; Steiner, LA, 2016) | 0.43 |
| " The dose-response relationship of carbetocin in obese women has not yet been determined." | ( Carbetocin at elective caesarean section: a sequential allocation trial to determine the minimum effective dose in obese women. Balki, M; Carvalho, JCA; Downey, K; Drew, T; Farine, D; Ye, XY, 2020) | 0.56 |
| " The standard carbetocin dosing was 100 µg iv following vaginal and intrapartum Cesarean delivery, while for elective Cesarean delivery it was 50 µg, with an additional 50 µg if required." | ( Carbetocin versus oxytocin following vaginal and Cesarean delivery: a before-after study. Ben Tareef, A; Carvalho, JCA; Downey, K; Ma, B; Whittle, WL, 2022) | 0.72 |
| " Le dosage standard de carbécotine était de 100 μg iv après un accouchement vaginal et pendant un accouchement par césarienne intrapartum, tandis que pour un accouchement par césarienne élective, le dosage était de 50 μg, avec 50 μg supplémentaires au besoin." | ( Carbetocin versus oxytocin following vaginal and Cesarean delivery: a before-after study. Ben Tareef, A; Carvalho, JCA; Downey, K; Ma, B; Whittle, WL, 2022) | 0.72 |
| Role | Description |
|---|---|
| oxytocic | A drug that stimulates contraction of the myometrium. Oxytocics are used to induce labour, obstetric at term, to prevent or control postpartum or postabortion haemorrhage, and to assess foetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (abortifacients). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| heterodetic cyclic peptide | A heterodetic cyclic peptide is a peptide consisting only of amino-acid residues, but in which the linkages forming the ring are not solely peptide bonds; one or more is an isopeptide, disulfide, ester, or other bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Oxytocin receptor | Homo sapiens (human) | Ki | 0.0018 | 0.0001 | 0.0718 | 0.9780 | AID1593563 |
| Vasopressin V1a receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0006 | 0.3835 | 2.0000 | AID1178653 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Vasopressin V2 receptor | Homo sapiens (human) | EC50 (µMol) | 2.6567 | 0.0000 | 0.5506 | 6.7000 | AID1178647; AID1386968; AID1386974 |
| Oxytocin receptor | Homo sapiens (human) | EC50 (µMol) | 0.0109 | 0.0000 | 0.0805 | 0.8810 | AID1178646; AID1386960; AID1386975; AID1528624; AID1593562 |
| Vasopressin V1a receptor | Homo sapiens (human) | EC50 (µMol) | 0.0217 | 0.0000 | 0.1971 | 3.2000 | AID1178648; AID1593564 |
| Vasopressin V1b receptor | Homo sapiens (human) | EC50 (µMol) | 12.3349 | 0.0000 | 0.0360 | 0.2400 | AID1178649; AID1386966; AID1593565 |
| Oxytocin receptor | Mus musculus (house mouse) | EC50 (µMol) | 0.0620 | 0.0020 | 0.0427 | 0.0780 | AID1386962 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1386964 | Agonist activity at human V1a receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1882821 | Stability of the compound in simulated gastric fluid at pH 1.2 assessed as half life measured up to 24 hrs by RP-HPLC-UV analysis | 2022 | Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8 | On the Utility of Chemical Strategies to Improve Peptide Gut Stability. |
| AID1593566 | Selectivity ratio of EC50 for recombinant human V1a receptor expressed in HEK293 cells to EC50 for recombinant human OTR expressed in HEK293 cells | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. |
| AID1386976 | Agonist activity at human OTR receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay relative to OT | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1528624 | Agonist activity at recombinant human Gi/Go-coupled OTR expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins in presence of 10% FBS by pathhunter assay | |||
| AID1178659 | Partial agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1528648 | Anorexigenic activity in C57BL/6J mouse diabetes induced obese model assessed as reduction in body weight at 0.1 mg/kg, sc administered once daily for 9 days and measured daily during compound dosing | |||
| AID1593563 | Displacement of [3H]OT from recombinant human OTR expressed in HEK293 cell membranes measured after 1 hr | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. |
| AID1593565 | Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. |
| AID1386977 | Agonist activity at human V1a receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1178649 | Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1528641 | Anorexigenic activity in C57BL/6J mouse assessed as reduction in food intake at 0.5 mg/kg, sc measured at 24 hrs post-dose | |||
| AID1386961 | Agonist activity at human OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to OT | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1178663 | Partial agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay relative to control | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1178650 | Selectivity ratio of EC50 for human vasopressin V2 expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1386980 | Agonist activity at human V2 receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay relative to AVP | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386962 | Agonist activity at mouse OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1593567 | Selectivity ratio of EC50 for recombinant human V1b receptor expressed in HEK293 cells to EC50 for recombinant human OTR expressed in HEK293 cells | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. |
| AID1178651 | Selectivity ratio of EC50 for human vasopressin V1a expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1593562 | Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. |
| AID1528644 | Anorexigenic activity in C57BL/6J mouse assessed as reduction in body weight at 0.5 mg/kg, sc measured daily for 2 days | |||
| AID1178652 | Selectivity ratio of EC50 for human vasopressin V1b expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1386974 | Agonist activity at human V2 receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1178647 | Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1882822 | Stability of the compound in simulated intestinal fluid at pH 6.8 assessed as half life measured up to 24 hrs by RP-HPLC-UV analysis | 2022 | Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8 | On the Utility of Chemical Strategies to Improve Peptide Gut Stability. |
| AID1386967 | Agonist activity at human V1b receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to AVP | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386978 | Agonist activity at human V1b receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1494508 | Agonist activity at human mammary gland oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 5 mins by Fluo-4-AM dye based FLIPR assay | 2018 | Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11 | Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs. |
| AID1386969 | Agonist activity at human V2 receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to AVP | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1528640 | Anorexigenic activity in C57BL/6J mouse assessed as reduction in food intake at 0.5 mg/kg, sc measured at 3 hrs interval for 6 hrs | |||
| AID1178653 | Antagonist activity at human vasopressin V1a expressed in AVP-stimulated HEK293 cells after 5 hrs by firefly luciferase reporter gene assay | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1386963 | Agonist activity at mouse OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to OT | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1593568 | Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method relative to oxytocin | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. |
| AID1528646 | Anorexigenic activity in C57BL/6J mouse diabetes induced obese model assessed as reduction in food intake at 0.1 mg/kg, sc administered once daily for 9 days and measured daily during compound dosing | |||
| AID1386975 | Agonist activity at human OTR receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386960 | Agonist activity at human OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1593564 | Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. |
| AID1386968 | Agonist activity at human V2 receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1528625 | Agonist activity at recombinant human Gi/Go-coupled OTR expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins in presence of 10% FBS by pathhunter assay relative to oxytocin | |||
| AID1528649 | Half life in C57BL/6J mouse | |||
| AID1178648 | Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1386966 | Agonist activity at human V1b receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1178646 | Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| AID1178656 | Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus dose | 2014 | Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12 | New, potent, and selective peptidic oxytocin receptor agonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (2.28) | 18.7374 |
| 1990's | 12 (5.48) | 18.2507 |
| 2000's | 25 (11.42) | 29.6817 |
| 2010's | 124 (56.62) | 24.3611 |
| 2020's | 53 (24.20) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 59 (25.99%) | 5.53% |
| Reviews | 27 (11.89%) | 6.00% |
| Case Studies | 4 (1.76%) | 4.05% |
| Observational | 7 (3.08%) | 0.25% |
| Other | 130 (57.27%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renal Effects of Carbetocin and Oxytocin in Cesarean Section for Preventing Post-partum Haemorrhage: a Prospective Randomized Study [NCT03939806] | 100 participants (Anticipated) | Observational | 2019-05-31 | Not yet recruiting | |||
| Carbetocin Versus Oxytocin Infusion Plus Tranexamic Acid for Prevention of Postpartum Hemorrhage at Cesarean Section: A Double-Blind Randomized Clinical Trial [NCT03777878] | 400 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | |||
| The Clinical Carbetocin Myocardium Trial [NCT02528136] | Phase 4 | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Carbetocin at Elective Cesarean Delivery: A Dose Finding Study [NCT01262742] | 80 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Carbetocin Versus Buccal Misoprostol Plus IV Tranexamic Acid for Prevention of Postpartum Hemorrhage at Cesarean Section: A Double-blind, Randomized, Placebo-controlled Trial [NCT03710317] | 400 participants (Actual) | Interventional | 2018-12-01 | Completed | |||
| The Effect of Carbetocin Versus Oral Tranexamic Acid Plus, Buccal Misoprostol on Blood Loss After Vaginal Delivery: a Randomized Controlled Trial [NCT03708497] | 360 participants (Actual) | Interventional | 2018-12-01 | Completed | |||
| CARBETOCIN VERSUS RECTAL MISOPROSTOL FOR MANAGEMENT OF THIRD STAGE OF LABOR IN WOMEN AT LOW RISK OF POSTPARTUM HEMORRHAGE [NCT03556852] | Phase 4 | 150 participants (Actual) | Interventional | 2018-07-02 | Completed | ||
| The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section [NCT02053922] | Phase 3 | 270 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia. [NCT02086994] | Phase 3 | 60 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| The Effect of Oral Tranexamic Acid Plus, Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage (PPH) After Vaginal Delivery: a Randomized Controlled Trial [NCT03870256] | 135 participants (Actual) | Interventional | 2019-04-01 | Completed | |||
| Routine Bilateral Uterine Artery Ligation During the Cesarean Delivery of Multiple Gestation [NCT05670886] | 110 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | |||
| Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With Twin Pregnancy. [NCT04182360] | 30 participants (Actual) | Interventional | 2021-10-14 | Completed | |||
| Carbetocin at Elective Cesarean Deliveries: A Non-inferiority Study Between 20 and 100 Micrograms - Part 4 [NCT02264769] | 110 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| Carbetocin vs. Oxytocin at Elective Cesarean Section: a Double-blind, Randomized Controlled Non-inferiority Trial of High and Low Dose Regimens [NCT03168698] | 278 participants (Actual) | Interventional | 2017-05-25 | Completed | |||
| Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage in Obese Women Undergoing Elective Cesarean Delivery [NCT03693599] | Phase 4 | 1,200 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With BMI ≥ 40kg/m2 [NCT03672045] | 30 participants (Actual) | Interventional | 2018-11-19 | Completed | |||
| Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section [NCT02079558] | Phase 2 | 220 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients With Stenotic Valvular Heart Disease Undergoing Caesarean Section [NCT05110482] | Phase 4 | 38 participants (Anticipated) | Interventional | 2021-11-30 | Enrolling by invitation | ||
| Carbetocin in the Prevention of Primary Postpartum Haemorrhage in Obese Versus Non-obese Women Undergoing Elective Cesarean Section [NCT06159959] | 244 participants (Actual) | Observational | 2023-01-01 | Completed | |||
| The Efficacy of Four Different Treatment Regimes of Uterotonic Agents for Prevention of Postpartum Hemorrhage at Vaginal Delivery: A Multicentric Randomized Controlled Trial [NCT05467462] | 300 participants (Actual) | Interventional | 2022-08-01 | Completed | |||
| Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Undergoing Caesarean Sections for Placenta Previa: A Randomised Controlled Trial [NCT02303418] | Phase 3 | 500 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial [NCT02304042] | Phase 3 | 200 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: a Double Blind Randomized Controlled Trial [NCT01382732] | Phase 3 | 636 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| Randomized Controlled Comparison of Blood Loss in Patients Who Received Oxytocin Infusion, Oxytocin Infusion, and Intrauterine Misoprostol and Carbetocin During Cesarean Delivery [NCT05083910] | 156 participants (Actual) | Interventional | 2021-07-01 | Completed | |||
| Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Post-partum Hemorrhage (PPH) After Vaginal Delivery: a Randomized Controlled Trial [NCT03870503] | 135 participants (Actual) | Interventional | 2019-04-01 | Completed | |||
| Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS) [NCT03649477] | Phase 3 | 130 participants (Actual) | Interventional | 2018-11-20 | Completed | ||
| Heat Stable Carbetocin Versus Oxytocin for the Prevention of Primary Postpartum Hemorrhage in Emergency Caesarean Delivery [NCT03755531] | Phase 4 | 300 participants (Actual) | Interventional | 2018-01-04 | Completed | ||
| Double-blind Randomised Non-inferiority Trial to Assess Efficacy and Safety of Carbetocin After Caesarean Section Applied as Iv-bolus as Compared to a Short-infusion [NCT02221531] | Phase 4 | 140 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Carbetocin Versus Oxytocin and Ergometrine for Prevention of Postpartum Hemorrhage Following a Cesarean Section in Women With Multiple Gestation [NCT03578263] | 220 participants (Actual) | Interventional | 2018-04-01 | Completed | |||
| A Comparison Between Carbetocin, Oxytocin and Ergometrine in Prevention of Postpartum Haemorrhage Following Caesarean Section [NCT02101567] | Phase 4 | 200 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome [NCT06173531] | Phase 3 | 170 participants (Anticipated) | Interventional | 2023-11-27 | Enrolling by invitation | ||
| Compariıson Of The Effects Of Carbetocin And Oxytocin, Which Are Uterotonic Agents, In C-Section Operations [NCT05742854] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-03-09 | Not yet recruiting | ||
| Carbetocin Versus Oxytocin Plus Misoprostol in Decreasing Intraoperative Blood Loss in Women Undergoing Planned Cesarean Section [NCT05664659] | Phase 4 | 90 participants (Actual) | Interventional | 2022-12-20 | Completed | ||
| Carbetocin Versus Oxytocin for Prevention of Postcesarean Hemorrhage in Pregnant Women With High Risk Postpartum Hemorrhage: a Randomized Controlled Trial [NCT04089176] | Early Phase 1 | 120 participants (Actual) | Interventional | 2019-02-01 | Completed | ||
| Adjuvant Use of Misoprostol and Oxytocin vs. Carbetocin for the Prevention of Post-partum Hemorrhage in Elective Cesarian Section [NCT02786992] | Phase 2/Phase 3 | 600 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Carbetocin Versus Ergometrin in the Prevention of Postpartum Hemorrhage in Parturients Undergoing Caesarian Section Under Regional Anaesthesia. A Single Blind Randomized Control Trial [NCT04300452] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-04-05 | Recruiting | ||
| Undesired Effects of Carbetocin Compared To Oxytocin Administered As Single Intravenous Dose or Infusion During Cesarean Delivery: A Prospective Randomised Controlled Study [NCT05758012] | 260 participants (Anticipated) | Observational | 2023-05-01 | Not yet recruiting | |||
| the Effect of Carbetocin in Decreasing Intraoperative Blood Loss in Abdominal Myomectomy: a Randomized Controlled Trial [NCT04083625] | Phase 4 | 138 participants (Actual) | Interventional | 2019-09-10 | Completed | ||
| Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section [NCT02044549] | Phase 4 | 300 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Carbetocin Versus Misoprostol for Prevention of Postpartum Hemorrhage in Pregnant Women at High Risk Following C.S. [NCT02277067] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| The Effect of Carbetocin Dose on Dispersion of Myocardial Repolarization in Healthy Parturients Scheduled for Elective Cesarean Delivery Under Spinal Anesthesia [NCT03716076] | Phase 4 | 50 participants (Actual) | Interventional | 2018-11-01 | Completed | ||
| Analgesic Effect of Oxytocin Receptor Modulation in Healthy Volunteers [NCT01918475] | 25 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparing Preoperative Vaginal Misoprostol, Intraoperative Oxytocin Infusion, Intravenous Carbetocin and Pericervical Hemostatic Tourniquet in Reducing Blood Loss During Abdominal Myomectomy, a Randomized Controlled Trial [NCT04595812] | Phase 4 | 120 participants (Anticipated) | Interventional | 2020-11-01 | Not yet recruiting | ||
| Carbetocin Versus Misoprostol in Reducing Blood Loss During Cesarean Section in Low Risk Patients. A Retrospective Comparative Study [NCT04313218] | 300 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Oxytocin Vs Carbetocin at Cesarean Delivery in Women With Morbid Obesity: Double-blind, Randomised Control, Non-inferiority Trial [NCT04902729] | 48 participants (Actual) | Interventional | 2021-07-20 | Completed | |||
| Cardiovascular Effects of Carbetocin During Elective Caesarean Delivery: A Randomized Controlled Trial Comparing Infusion Versus Bolus Administration Using Nexfin™ [NCT02636816] | Phase 4 | 57 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain, A Prospective Randomised Study [NCT02642263] | Phase 4 | 78 participants (Anticipated) | Interventional | 2019-02-01 | Not yet recruiting | ||
| Carbetocin at Elective Cesarean Delivery: A Dose Finding Study (Part 2) [NCT01428817] | 120 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| A Randomized, 2-Part, Crossover Trial to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects [NCT05924321] | Phase 1 | 40 participants (Actual) | Interventional | 2023-05-25 | Completed | ||
| Hemodynamic Effects of Carbetocin 100 µg, Oxytocin 5 U or Placebo After Cesarean Delivery Under Spinal Anesthesia in Healthy Pregnant Women. [NCT00977769] | Phase 4 | 76 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Carbetocin Versus Syntometrine for the Third Stage of Labour Following Vaginal Delivery - A Double-blind Randomised Trial [NCT00499005] | Phase 4 | 720 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
| Carbetocin Versus Misoprostol for Prevention of Postpartum Hemorrhage in Cases With Placenta Previa After C.S. [NCT02277041] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Evaluating Efficacy of Intravenous Carbetocin Versus Intramyometrial Injection of Adrenaline in Reducing Blood Loss During Abdominal Myomectomy: A Randomized Controlled Trial [NCT05986266] | Phase 1 | 62 participants (Actual) | Interventional | 2023-02-01 | Completed | ||
| Carbetocin at Cesarean Delivery for Labor Arrest: A Dose Finding Study [NCT01725243] | 40 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study Part 3 [NCT01651130] | 40 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| Prospective Observational Database Evaluating Outcomes of Using Carbetocin (Duratocin®) as the Primary Uterotonic Following Cesarean Delivery at Maisonneuve-Rosemont Hospital [NCT03959436] | 612 participants (Actual) | Observational [Patient Registry] | 2017-03-29 | Completed | |||
| Uterine Electromyography for Estimation of Uterotonic Efficiency for Postpartum Hemorrhage Prevention [NCT04201665] | 60 participants (Actual) | Interventional | 2020-09-13 | Completed | |||
| [NCT01827124] | Phase 4 | 140 participants (Anticipated) | Interventional | 2013-04-30 | Recruiting | ||
| Intramuscular Oxytocics: A Randomised Control Trial of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth [NCT02216383] | Phase 3 | 5,798 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Carbetocin vs. Oxytocin: In-vitro Myometrial Contractions With and Without Oxytocin Pre-treatment [NCT01689298] | 20 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial [NCT01600612] | 300 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | |||
| Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony During Elective Cesarean Section: a Randomized Controlled Trial [NCT01630187] | Phase 4 | 72 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Comparison of Haemodynamic and Cardiovascular Effects of Carbetocin and Oxytocin in Women Undergoing Elective Caesarean Section: A Double-blinded Randomised Clinical Trial [NCT01719952] | 50 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Comparing the Effectiveness of Misoprostol, Oxytocin, Carbetocin, Vasopressin, Bupivacaine and Epinephrine, Combined IV TXA Acid and Ethamsylate and Peri Cervical Tourniquet for the Reduction of Blood Loss During of Abdominal Myomectomy. [NCT05806307] | Phase 4 | 105 participants (Anticipated) | Interventional | 2023-03-15 | Recruiting | ||
| Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial [NCT02304055] | Phase 3 | 100 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Intramyometrial and Intravenous Oxytocin Compared to Intravenous Carbetocin for Prevention of Postpartum Hemorrhage in Elective Cesarean Sections - a Monocentric Randomized Controlled Study [NCT03651882] | Phase 4 | 550 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| Carbetocin Versus Combined Oxytocin and Misoprostol for Prevention of Postpartum Hemorrhage in Women With Severe Preeclampsia [NCT04756661] | 124 participants (Actual) | Interventional | 2020-01-01 | Completed | |||
| Carbetocin Versus Oxytocin for Prophylaxis Against Atonic Primary Post-partum Hemorrhage in High-risk Patients in Sohag University Hospital: A Randomized Controlled Clinical Trial [NCT05479357] | 80 participants (Anticipated) | Interventional | 2022-07-28 | Not yet recruiting | |||
| Comparative Safety and Efficacy of Intravenous Tranexamic Acid Versus IV Carbetocin in Reducing Blood Loss During Abdominal Myomectomy: a Randomized Controlled Trial [NCT04357015] | Phase 4 | 153 participants (Anticipated) | Interventional | 2020-05-01 | Not yet recruiting | ||
| ED90 Determination of Carbetocin for the Prevention of Postpartum Uterine Atony in Women Undergoing an Elective Cesarean Delivery [NCT01579201] | Phase 4 | 40 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| Evaluation of the Impact of Carbetocin Administration (Bolus Versus Infusion) on Heart Rate and Other Hemodynamic Parameters. [NCT03404544] | Phase 4 | 70 participants (Actual) | Interventional | 2018-06-11 | Completed | ||
| Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy: a Randomized Controlled Trial [NCT04482959] | Phase 4 | 40 participants (Actual) | Interventional | 2020-07-15 | Completed | ||
| Comparison Between Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage: A Randomized Controlled Trial [NCT02391636] | Phase 4 | 264 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [NCT02396303] | Early Phase 1 | 100 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial [NCT02410759] | Phase 3 | 200 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | ||
| The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets. [NCT05266534] | 162 participants (Anticipated) | Interventional | 2021-12-30 | Recruiting | |||
| The Efficacy and Safety of Tranexamic Acid Versus Uterotonic Agents in Reducing Blood Loss During and After Cesarean Section Among High-risk Patients: a Comparative Study [NCT06060327] | 444 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | |||
| The Clinical Carbetocin Myocardium Trial Part 2 [NCT03899961] | Phase 4 | 240 participants (Actual) | Interventional | 2019-04-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||